The Dulaglutide segment dominated the market with a share of 36.84% in 2025 due to its strong clinical efficacy, convenient once-weekly dosing schedule, proven cardiovascular benefits, and extensive physician adoption across diabetes treatment programs
According to the FDAs FAERS database, the number of adverse reactions each year since Ozempic, Rybelsus and Wegovy were released have climbed significantly, reaching a total of 18,846 adverse events as of June 30, 2023
Synthesis of chemicals by metabolic engineering of microbes
Intestinal OCTN2- and MCT1-targeted drug delivery to improve oral bioavailability
Generally, antacids are safe to use with GLP-1s, provided you follow professional guidance and understand how your body processes them